{
    "clinical_study": {
        "@rank": "94309", 
        "arm_group": {
            "arm_group_label": "Arm I", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive intravenous flavopiridol over 72 hours every 2 weeks for at least 4 courses. After 2 courses of treatment, patients not experiencing unacceptable toxic effects may receive a dose escalation."
        }, 
        "brief_summary": {
            "textblock": "Phase II trial to study the effectiveness of flavopiridol in treating patients with\n      recurrent prostate cancer after hormone therapy. Drugs used in chemotherapy use different\n      ways to stop tumor cells from dividing so they stop growing or die."
        }, 
        "brief_title": "Flavopiridol in Treating Patients With Recurrent Prostate Cancer", 
        "completion_date": {
            "#text": "April 2004", 
            "@type": "Actual"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n      I. Evaluate the clinical effectiveness of flavopiridol in patients with metastatic androgen\n      independent adenocarcinoma of the prostate.\n\n      II. Assess the toxic effects of flavopiridol in this patient population.\n\n      OUTLINE:\n\n      Patients receive intravenous flavopiridol over 72 hours every 2 weeks for at least 4\n      courses. After 2 courses of treatment, patients not experiencing unacceptable toxic effects\n      may receive a dose escalation. Patients are followed every 3 months until death."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PATIENT CHARACTERISTICS:\n\n          -  Performance Status: ECOG 0-2\n\n          -  Life Expectancy: At least 3 months\n\n          -  WBC at least 3,000/mm3\n\n          -  Absolute neutrophil count at least 1,200/mm3\n\n          -  Platelet count at least 100,000/mm3\n\n          -  Hemoglobin at least 8 g/dL\n\n          -  Bilirubin no greater than 1.5 mg/dL\n\n          -  SGOT no greater than 2.5 times normal\n\n          -  Creatinine no greater than 1.5 mg/dL\n\n          -  Prostate-specific antigen at least 10 ng/mL (if bone only disease)\n\n          -  No prior or concurrent maligancies within 5 years, except nonmelanoma skin cancer\n\n          -  No serious medical illness\n\n          -  No cord compression symptoms\n\n        PRIOR CONCURRENT THERAPY:\n\n          -  No prior chemotherapy\n\n          -  No prior suramin therapy\n\n          -  Prior or concurrent use of luteinizing hormone-releasing hormone allowed (no other\n             concurrent hormonal therapy)\n\n          -  No prior anti-androgen therapy within 4 weeks of study\n\n          -  At least 4 weeks since prior radiotherapy\n\n          -  No prior strontium therapy"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 1, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00003256", 
            "org_study_id": "CDR0000066145", 
            "secondary_id": [
                "WCCC-CO-9781", 
                "NCI-T97-0038"
            ]
        }, 
        "intervention": {
            "arm_group_label": "Arm I", 
            "intervention_name": "alvocidib", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Flavopiridol"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "adenocarcinoma of the prostate", 
            "stage IV prostate cancer"
        ], 
        "lastchanged_date": "February 8, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/WCCC-CO-9781"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Duarte", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91010"
                    }, 
                    "name": "Beckman Research Institute, City of Hope"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sacramento", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "95817"
                    }, 
                    "name": "University of California Davis Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02115"
                    }, 
                    "name": "Dana-Farber Cancer Institute"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madison", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "53792"
                    }, 
                    "name": "University of Wisconsin Comprehensive Cancer Center"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Trial of Flavopiridol in Patients With Metastatic Androgen Independent Prostate Cancer", 
        "overall_official": {
            "affiliation": "University of Wisconsin, Madison", 
            "last_name": "George Wilding, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2002", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00003256"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "results_reference": {
            "PMID": "14871968", 
            "citation": "Liu G, Gandara DR, Lara PN Jr, Raghavan D, Doroshow JH, Twardowski P, Kantoff P, Oh W, Kim K, Wilding G. A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer. Clin Cancer Res. 2004 Feb 1;10(3):924-8."
        }, 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "May 1998", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }, 
    "geocoordinates": {
        "Beckman Research Institute, City of Hope": "34.139 -117.977", 
        "Dana-Farber Cancer Institute": "42.358 -71.06", 
        "University of California Davis Cancer Center": "38.582 -121.494", 
        "University of Wisconsin Comprehensive Cancer Center": "43.073 -89.401"
    }
}